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Abstract
Background: A 24-day regimen of contraceptive doses of drospirenone and ethinylestradiol (DRSP/EE 24d) was
recently launched. This regimen has properties which may be beneficial for certain user populations (e.g., women
suffering from premenstrual dysphoric disorder or acne). However, it is unknown whether this extended regimen has
an impact on the cardiovascular risk associated with the use of oral contraceptives (OCs). The INternational Active
Surveillance study of women taking Oral Contraceptives (INAS-OC) is designed to investigate the short- and long-term
safety of the new regimen in a population which is representative for the typical user of oral contraceptives.
Methods/Design: A large, prospective, controlled, non-interventional, long-term cohort study with active surveillance
of the study participants has been chosen to ensure reliable and valid results. More than 2,000 gynecologists in the US
and 5 European countries (Austria, Germany, Italy, Poland, and Sweden) will recruit more than 80,000 OC users. The
two to five year follow-up of these women will result in at least 220,000 documented women-years.
The main clinical outcomes of interest for the follow-up are deep venous thrombosis, pulmonary embolism, acute
myocardial infarction and cerebrovascular accidents. Secondary objectives are general safety, effectiveness and drug
utilization pattern of DRSP/EE 24d, return to fertility after stop of OC use, as well as the baseline risk for users of
individual OC formulations.
Because of the non-interference character of this study, potential participants (first-time users or switchers) are informed
about the study only after the decision regarding prescription of a new OC. There are no specific medical inclusion or
exclusion criteria. Study participation is voluntary and a written informed consent is required. After the baseline
questionnaire, follow-up questionnaires will be mailed to the participants every 6 months for up to 5 years after baseline.
Self-reported serious adverse events will be validated by contacting the relevant physician and by reviewing relevant
source documents. At the end of the study an independent blinded adjudication of relevant clinical outcomes will be
conducted.
Meanwhile, this study has received ethical approval from the Western Institutional Review Board (USA) and the Medical
Association in Berlin (Germany).
Discussion: The feasibility of the study is considered to be very high because of its similar design to the EURAS-OC
study. All relevant methodological and logistical features of the study were successfully tested in the EURAS study.
The chosen design minimizes the impact of referral and misclassification bias, healthy user effect and loss to follow-up. 
Overall, it is expected that the study design is robust enough to interpret hazard ratios of 1.5 or higher.
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Background
Since their introduction in the mid-1960s, oral contracep-
tives have become a very popular method of birth control.
Their safety has been improved over the years with the
reduction in the doses of estrogen and progestogen. How-
ever, concerns about their safety have remained, peaking
in the mid-1990s with the discussion on whether so-
called "third generation" progestogens (desogestrel and
gestoden) have a higher risk of cardiovascular side effects
(especially venous thromboembolism - VTE) than older
formulations. A number of studies have been published
with conflicting results. Most of these studies have sub-
stantial methodological shortcomings and the discussion
on the impact of bias and confounding on the results has
not been resolved [1-17].
In the early 2000s the new progestogen drospirenone
(DRSP) was introduced. Five studies investigated the VTE
risk associated with the combination of 3 mg DRSP and
30 mcg ethinylestradiol (EE) given for 21 days per cycle
(DRSP/EE 21d). Two large prospective cohort studies
came to the conclusion that the combination of 3 mg
DRSP and 30 mcg ethinylestradiol (EE) given for 21 days
per cycle (DRSP/EE 21d) are as safe as OCs containing EE
and levonorgestrel with regard to venous thromboembo-
lism (essentially deep venous thrombosis and pulmonary
embolism) and arterial thromboembolism (essentially
acute myocardial infarction and cerebrovascular acci-
dents) [12,13]. A case-control study in The Netherlands
[14] and a large retrospective Danish cohort study using
information from the Danish registries [15] found that
DRSP might increase the risk for VTE compared to lev-
onorgestrel-containing combined oral contraceptives.
However, the results of the Dutch study were not statisti-
cally significant and the risk estimates of the Danish study
were not adjusted for important confounders. In addition,
the Danish study underestimated the VTE risk associated
with the use of levonorgestrel-containing preparations
because of differential misclassification of duration of use.
The fifth study - a German case-control study [16] did not
find an increased risk for DRSP/EE 21d, but the results
have been published only as an abstract. A more detailed
review of the four studies is published elsewhere [17]. All
five studies investigated the 21-day regimen of DRSP.
Overall, the existing evidence suggests that the VTE risk
associated with the use of DRSP/EE 21d is similar to the
VTE risk associated with OCs containing other pro-
gestogens.
This study investigates a 24-day regimen of a combination
of 3 mg DRSP and 20 mcg EE (DRSP/EE 24d): 24 days of
active pills are followed by 4 days of placebo pills. Based
on the lower estrogen dose of DRSP/EE 24d, it can be
assumed that a 21-day regimen of this pharmaceutical for-
mulation would not be associated with a higher risk of
venous thromboembolism (VTE) than DRSP/EE 21d.
Clinical studies indicate that a 24-day regimen of contra-
ceptive doses of drospirenone and ethinylestradiol
(DRSP/EE 24d) leads to stable hormone levels in the
blood and a strong suppression of ovarian activity [18]. In
addition, DRSP has antiandrogenic and antimineralocor-
ticoid properties [19]. Compared to other oral contracep-
tives (OC) the new regimen may lead to better
contraceptive effectiveness and better control of premen-
strual symptoms.
It is unknown, however, whether the extended 24-day reg-
imen has an impact on the cardiovascular risk associated
with the use of oral contraceptives. Though the 24-day
regimen is not expected to have a negative impact on the
risk of VTE and arterial embolism (ATE) compared to a
21-day regimen, a study to assess this impact was deemed
appropriate. It is conceivable that the reduction in so-
called hormone swings leads to a lower incidence of
venous thromboembolism. It is also conceivable, how-
ever, that the higher cumulative doses of progestin and
estrogen lead to a higher risk. This non-interventional
post-authorization safety study (PASS) is a phase IV com-
mitment to the FDA. The study proposed in this protocol
should provide data that are sufficiently robust to show
that there is no increase in VTE risk for DRSP/EE 24d.
The EURAS study has demonstrated that a large, prospec-
tive, controlled, non-interventional, long-term cohort
study is suitable for
1. Safety monitoring of an oral contraceptive
2. Reliable identification of relevant clinical outcomes
and
3. Providing robust estimates of their incidence.
The INAS-OC Study has a similar study design but the
procedures for recruitment, informed consent and follow-
up were slightly modified to comply both with European
and US regulations, and to ensure good recruitment rates
and low loss to follow-up in a transatlantic environment.
The study should provide early information and regular
updates on relevant clinical outcomes which will contrib-
ute to a continuous risk - benefit assessment during long-
term follow up (3 to 5 years in the US, 2 to 4 years in
Europe).
The US part of the study started already in August 2005,
because of the early launch of DRSP/EE 24d in the US. TheBMC Medical Research Methodology 2009, 9:77 http://www.biomedcentral.com/1471-2288/9/77
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European part of the study started in fall 2008 with the
market introduction of DRSP/EE 24d in Europe.
The primary objective of the study is to assess the risks of
short and long-term use of DRSP/EE 24d and of estab-
lished OCs in a study population that is representative for
the actual users of the individual preparations. This
includes an estimate of the absolute risk of rare serious
adverse outcomes.
The main clinical outcomes of interest for the short and
long-term follow-up are:
• Venous Thromboembolism (VTE; mainly Deep Venous
Thrombosis (DVT) and Pulmonary Embolism (PE))
￿ Arterial Thromboembolism (ATE; mainly Acute Myocar-
dial Infarction and cerebrovascular accidents (CVA))
Secondary objectives are:
￿ to investigate the general safety and effectiveness of
DRSP/EE 24d under real-life conditions in typical user
populations (e.g., obese women, adolescents)
￿ to investigate return to fertility in users who stop OC use
because of a planned pregnancy
￿ to analyze the drug utilization pattern of DRSP/EE 24d
and established OCs in a study population that is repre-
sentative for typical use of the individual preparations
under routine medical conditions in Europe and the
United States. Interference of study-specific requirements
and measures with the normal drug utilization pattern
should be minimized by using a non-experimental study
design
￿ to characterize the baseline risk of users of the individual
formulations (lifetime history of co-morbidity, risk mark-
ers, co-medication, socio-demographic and lifestyle data)
Methods/Design
The INAS-OC Study is a large, transatlantic, prospective,
controlled, non-interventional, long-term cohort study
that follows a series of cohorts. The cohorts consist of new
users (first-ever users or switchers) of two different groups
of OCs: OCs containing DRSP and OCs containing other
progestins ("Other OCs" cohort). Each of these two
cohorts will be divided in two sub-cohorts: a) the DRSP
cohort into a 24-day regimen (DRSP/EE 24d) and a 21-
day regimen (DRSP/EE 21d) sub-cohort, and b) the
"other progestins" cohort into a sub-cohort of levonorg-
estrel (LNG)-containing OCs and a sub-cohort of all other
progestin-containing OCs. A "non-interference" approach
will be used. This means that 1) all patients who are new
users of an OC are eligible for enrollment if they give their
informed consent and 2) the recruitment of patients
should not (significantly) influence the physician's pre-
scribing behavior. This approach is used to provide stand-
ardized, comprehensive, reliable information on these
groups of OCs under routine medical conditions. In this
study, regular, active contacts with the cohort members (=
active surveillance) should provide all necessary informa-
tion on health-related events or changes in health status.
Besides baseline, contacts to obtain information are
planned every six month for a maximum of 4 years (48
months after baseline) in Europe and 5 years (54 months
after baseline) in the US. By means of these contacts,
almost all relevant clinical outcomes will be captured.
However, laypersons often misclassify adverse events
(e.g., pain in the legs after standing a long period of time
as "thrombosis" or migraine attacks as "stroke" even if
modern imaging procedures do not provide any indica-
tion of the perceived event). This type of inaccuracy in
patient reports will require careful validation of the
reported events. This will be accomplished by contacting
the relevant physicians and by reviewing relevant source
documents. Under routine medical conditions, diagnosis
of a VTE it is not always confirmed by an imaging proce-
dure. Therefore, reported VTEs have to be classified as
"confirmed" or "not confirmed" according to a predefined
algorithm. At the end of the study a blinded adjudication
will be conducted to verify this classification. Three inde-
pendent medical experts with experience in VTE will
review all available information on the reported VTEs. For
this process the brand names, dose, regimen and compo-
sition of the OCs will be rendered anonymous. The adju-
dicators will perform the reviews independently of each
other and without knowing the judgment of the other
adjudicators or the investigators.
The adjudication procedure will include the following
steps:
1) Independent adjudication by the individual spe-
cialists
2) Documentation of the individual assessments
3) Comparison of the individual assessments
4) Discussion of "split decisions" among the adjudica-
tors without enforcement of a unanimous decision
5) Independent re-adjudication of the discussed cases
by the individual adjudicators
6) Documentation of the individual assessmentsBMC Medical Research Methodology 2009, 9:77 http://www.biomedcentral.com/1471-2288/9/77
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The final analysis will be based on a strategy where at least
one adjudicator has classified the event as confirmed
before the discussion took place, because it represents the
most conservative approach. However, alternative analy-
ses can be conducted, if requested by regulatory authori-
ties.
The same procedure will be used for the adjudication of
ATE. Based on interim results the independent Safety
Monitoring and Advisory Board may decide to use the
same adjudication procedure for other outcomes of inter-
est too.
Study Centers
Recruitment of the cohort members is conducted via a
network of approximately 2000 OC prescribing physi-
cians in Europe (Austria, Germany, Poland, and Sweden)
and the United States.
The combined cohort will include approx. 80,000
women, with about 50,000 women in the US and 30,000
women in Europe. Study measures should not interfere
with the prescribing behavior of physicians or with the
individual needs of the participating women. Influence
on the preference for specific OCs is to be avoided but sig-
nificant efforts are to be undertaken to ensure standard-
ized, comprehensive and reliable documentation of all
baseline characteristics and adverse events during the fol-
low-up period.
Study Participants
The study participants are women who
￿ have a prescription for a new OC
￿ are willing to participate in this long-term follow-up
study
These women can be either OC starters (first-ever user) or
OC switchers. There are no specific medical inclusion or
exclusion criteria. However, women
￿ who are not cooperative and/or available for follow-
up may be excluded from study participation
￿ with a language barrier will not be eligible for study
inclusion, as all materials are printed in the country-
specific language
At the participating centers, all women seeking a prescrip-
tion for a new OC are to be asked by their physician if they
are willing to participate. The physician should explain
the nature of the study, its purpose and associated proce-
dures, and the expected duration of follow-up to each
woman prior to her study entry. Each woman must have
ample opportunity to ask questions and has to be
informed about her right to withdraw from the study at
any time without disadvantage and without having to
provide reasons for her decision. This information will be
provided on an informed consent and data privacy form
which must be signed by all study participants prior to
study entry. These documents are to be approved by the
relevant Ethics Committees and the relevant Data Privacy
Offices, if applicable.
The whole process of patient information of this study
should not start before the discussion and prescription of
the new OC has taken place.
Once enrolled, a subject may discontinue the use of her
OC at any time. However, subjects will continue to be fol-
lowed up whether or not they remain on OCs, provided
that they do not withdraw their consent. During the fol-
low-up phase, subjects will be asked whether they have
discontinued OC use or whether they have switched to
another OC preparation. Information on the date and rea-
son for discontinuation or switching during the follow-up
phase will also be collected.
Baseline Survey
Each physician's office will be provided with question-
naires for collecting data at baseline. The baseline visit will
take place at the participating physician's office. All
women who receive a new prescription for an oral contra-
ceptive are to be asked if they are willing to participate.
The physician will not discuss the study with the women
until the OC has been prescribed. This ensures that partic-
ipation in the study is not considered a requirement for
treatment. After discussing the study details (including
follow-up procedures and intervals, content and duration
of follow-up contacts, use of data collected, etc.), each
subject will be asked to provide written informed consent
to participate in the study. If the subject needs time to con-
sider participation, she can leave the physician's office
with her prescription and take an appropriate period of
time to decide whether to participate or not. If she decides
to take part in this study, she hands in the signed docu-
ments at the physicians' office.
Baseline data are to be recorded on a self-administered
questionnaire containing questions relating to the partic-
ipant's state of health, potential risk factors and history of
medication and OC use. The patient is also asked to pro-
vide her own address, e-mail address and phone number
as well as the contact information of a relative or friend for
alternative contact in case the study participant can not be
reached. In compliance with data protection regulations
names, addresses and phone numbers are documented on
a separate sheet.BMC Medical Research Methodology 2009, 9:77 http://www.biomedcentral.com/1471-2288/9/77
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Follow-up
Patients will be recruited within the first 2 years after the
market introduction of DRSP/EE 24d and follow-up is
scheduled every 6 month for up to 4 years in Europe and
up to 5 years in the United States. The follow-up question-
naires include data on the occurrence of adverse events,
exact dates for using, stopping or switching OCs, as well
as changes in risk factors relevant to VTE and ATE. Ques-
tionnaires will be mailed to the participating women, who
often know more about their own personal health related
issues than the physician who prescribes their OC. This
can especially be true for information on adverse events
that are treated by other physicians. Experiences with this
study design show, that events may be reported sporadi-
cally by the participant or by relatives, friends or attending
physicians between the regular follow-ups. These reports
will be documented and validated in the same way as reg-
ular reports.
A low "lost to follow-up rate" will be essential for the
validity of the study. In order to minimize loss to follow-
up a multi-faceted, four-level follow-up process will be
established. Level1 activities include mailing of the fol-
low-up questionnaire and - in case of no response - two
reminder letters. If level1 activities do not lead to a
response, multiple attempts are to be made to contact the
woman, friends, relatives and the Gynecologist/Primary
Care Physician per phone. In parallel to these level2 activ-
ities searches in national and international telephone and
address directories are started (level3 activities). If this is
not successful, an official address search via the respective
governmental administration will be conducted. This
level4 activity can provide information on new addresses
(or emigration or death). If necessary, a search in the
national death registers could be started at the end of the
study to clarify the vital status of patients who are lost to
follow-up after level4 activities. Overall, the loss to fol-
low-up of the combined cohort should be kept at less than
10% of the recruited population.
The follow-up questionnaires will address the occurrence
of adverse events. Reasons for switching to another OC or
discontinuation will be requested if applicable.
Validation of Self-Reported Events
Validation of self-reported events begins at the level of the
national field work organization with a review of all sub-
jective "events." This is followed by a further review at the
international coordinating center (ZEG).
If an event is reported by a participant, the subjectively
perceived symptoms, signs, and if possible the diagnoses
as understood by the patient should be recorded. The
name and address of the relevant physician ought to be
provided by the participant.
These report forms are to be immediately passed on to the
responsible medical reviewer/group. In case of unclear or
missing information, the woman will be contacted by tel-
ephone, e-mail or by other means of communication. For
many events it may be necessary to contact the diagnosing
and/or treating physician for clarification and validation
of the information received from the patient. This proce-
dure is mandatory for all serious clinical outcomes (Seri-
ous adverse event means any adverse event that results in
death, a life-threatening experience, inpatient hospitaliza-
tion, persistent or significant disability/incapacity, or
requires medical/surgical intervention to prevent one of
said outcomes). (incl. VTE and ATE).
Under routine medical conditions, diagnosis of a VTE it is
not always confirmed by an imaging procedure. There-
fore, reported VTE have to be classified as "confirmed" or
"not confirmed" according to the following predefined
algorithm:
I. Definite VTE: Confirmed by diagnostic measures
with high specificity.
DVT: phlebography, duplex sonography, magnetic res-
onance imaging
PE: pulmonary angiography, ventilation-perfusion
scan, spiral computed tomography, magnetic reso-
nance imaging, transesophageal echocardiography
II. Probable VTE: Clinical diagnosis confirmed by a
health professional, supported by an unspecific diag-
nostic test (such as D-dimer for VTE) and/or a subse-
quent specific therapy (such as fibrinolysis or long-
term anticoagulant therapy). However, if the attend-
ing physician confirmed the diagnosis, the event will
be classified as a probable event even if specific treat-
ment was not given or if positive test results are not
available.
III. No VTE:
- VTE excluded by an imaging procedure
- Other medical condition diagnosed by the
attending physician
- Woman does not contact a health professional to
clarify her symptoms and no diagnostic measures
are performed that could clarify the diagnosis
A VTE will be classified as "confirmed" if the diagnosis is
categorized as definite or probable according to the above
criteria, regardless of hospital admission or type of treat-
ment provided.BMC Medical Research Methodology 2009, 9:77 http://www.biomedcentral.com/1471-2288/9/77
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At the end of the study this classification will be checked
by blind independent adjudication. The Safety Monitor-
ing and Advisory Board will appoint three independent
medical experts who will review all available information
on the reported VTE. However, brand names, dose, regi-
men and composition of the OC(s) used by the reporting
woman will be rendered anonymous. The adjudicators
will perform the review independently of each other and
without knowing the judgment of the other adjudicators.
If at least one adjudicator classifies a report as confirmed
VTE, the reported event will be considered a confirmed
VTE (cf. Methods/Design).
Reporting of Serious and/or unexpected adverse events
ZEG will report all serious and/or unexpected events that
are possibly related to the use of any OC to the relevant
pharmaceutical companies. A physician on the ZEG study
team will assess the likelihood of a causal relationship to
OC use for each serious adverse event in accordance with
a predefined algorithm.
ZEG will not monitor whether the pharmaceutical com-
panies meet their obligation to report these events to the
Health Authorities according to (inter)national rules.
Data Management
When questionnaires are received from study participants,
all pages are counted and date-stamped. Questionnaires
are to be checked for correct subject identification
number, missing pages, legibility, and incomplete infor-
mation on the questionnaires. Missing pages, illegible or
missing information will be requested from the study par-
ticipants.
Data are entered by double data entry via formatted entry
screens designed to reflect the appearance of the question-
naire. Discrepancies between first and second data entry
are identified by comparison of the two entry files within
the statistical software SAS. The decision on the true entry
is done by the responsible data manager at ZEG. This may
require direct contact with the study participant who filled
in the questionnaire. Corrections will be made to the
questionnaire only after contact with the study participant
or her treating physician. All corrections are dated and ini-
tialled by the data manager who received the relevant new
information (e.g., via direct contact or by a copy of medi-
cal reports/documents). The incorrect CRF entry will be
crossed out; however, it must remain legible, and the cor-
rect entry will be placed next to it. The reason for any cor-
rection of medical data on the questionnaire must be
documented.
Quality control of entered data will be supported by SAS
plausibility programs which include range, coding, miss-
ing and date checks as well as cross-reference (consist-
ency) checks between variables.
Size of the Study
The study was designed to analyze rare events (according
to the CIOMS classification 1 - 10 events per 10,000
women years). The adverse events of particular interest are
VTE and ATE. Based on the EURAS results the estimated
VTE and ATE incidence rates in the young study popula-
tion are ~9/10,000 women years for VTE and ~2/10,000
WY for ATE.
The primary outcome of interest is the VTE hazard ratio
between DRSP/EE 24d and Other OCs. The null hypothe-
sis to be tested is: HRVTE > 2 (i.e., the VTE hazard ratio for
DRSP/EE 24d vs. Other OCs is higher or equal to 2). The
alternative hypothesis is: HRVTE < 2. In a sub-analysis VTE
hazard ratios will also be calculated for DRSP/EE 24d vs.
LNG-containing OCs.
The 2 to 5 years of follow-up of 80,000 women should
result in at least 220,000 documented women-years.
Based on the market shares of DRSP-containing and LNG-
containing OCs it is expected that the DRSP/EE 24d and
LNG exposure will be approx. 44,000 and 22,000 women-
years, respectively. Power calculations based on an one-
sided alpha of 0.025, a statistical power of 90%, and the
VTE incidence given above showed that approximately
90,000 women-years would be needed to show non-infe-
riority of DRSP/EE 24d versus "Other OCs". In addition,
approx. 42,600 and 21,300 women-years of DRSP/EE 24d
and LNG exposure would be needed to show non-inferi-
ority of DRSP/EE 24d versus LNG-containing OCs (i.e.,
slightly less than the expected exposure of 44,000 and
22,000 women-years). Furthermore, the study will have a
statistical power of 99% and 75% to exclude a threefold
and twofold risk of ATE, respectively.
In essence, the study is powered to exclude a twofold risk
of VTE and a threefold risk of ATE - if the true incidence
for the outcomes of interest is not different for the two
cohorts. The EURAS study, however, showed a low ATE
incidence for DRSP-containing OCs. If the INAS OC study
shows a similar low ATE incidence for DRSP/EE 24d the
power of the study will be sufficient to exclude a twofold
ATE risk for DRSP/EE 24d.
These power calculations suggest that the INAS OC study
is sufficiently powered to show non-inferiority of DRSP/
EE 24d compared to established OCs (including LNG-
containing OCs). However, exact power calculations
based on actual incidences and drop-out rates should be
done on the basis of one year of follow-up data. If these
calculations do not confirm the assumed incidences and
drop-out rates the independent Safety Monitoring andBMC Medical Research Methodology 2009, 9:77 http://www.biomedcentral.com/1471-2288/9/77
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Advisory Board (SMAB) may discuss the need for adapting
patient numbers and follow-up times.
Data Analysis
It is feasible to analyze the data for the US and the Euro-
pean part separately and draw conclusions from it.
The final analyses will include both an "as treated" (AT)
and where necessary also an intention-to-treat (ITT) anal-
ysis. The safety conclusions of the study, however, will be
based on the AT analyses because the ITT approach poten-
tially dilutes differences between treatments.
Crude as well as adjusted hazard ratios will be calculated.
The appropriate confounding variables will be built into
the model. Based on the expectation of a small absolute
number of serious outcomes of interest the number of
confounding variables will be limited to well established
risk factors for these outcomes (e.g., age, BMI, duration of
use, and VTE history). The final decision on the confound-
ing variables will be made by the Safety Monitoring and
Advisory Board before the first interim analysis of follow-
up data. In addition, alternative analysis will be per-
formed with other potential baseline risks to check the
appropriateness of this decision.
The principal investigator will present a detailed analysis
plan to the independent Safety Monitoring and Advisory
Board for approval before the first interim analysis of fol-
low-up data.
Safety Monitoring and Advisory Council
This study will maintain scientific independence and will
be governed by an independent Safety Monitoring and
Advisory Board throughout the study time. The council is
concerned with the safety of the oral contraceptives used
in this study and the protection of the public. Commercial
interests must not supersede the ethical principles of non-
maleficence (obligation not to inflict harm intentionally)
and beneficence (obligation to contribute to the welfare
of the patient). SMAC has full authority over the study.
This includes approval of study protocol, final study
report and publications emerging from the study, as well
as stopping the study for safety reasons, if necessary.
Bayer Schering Pharma AG provided an unconditional
grant. The Berlin Center for Epidemiology and Health
Research (ZEG), Germany and its investigator team will
be accountable to the Safety Monitoring and Advisory
Board in all scientific matters. The investigators update the
SMAC members on study status and interim results at
least twice a year. SMAC's conclusions and decisions are
made in executive session without attendance of the
investigators or representatives of Bayer Schering Pharma
AG.
The SMAC members (Samuel Shapiro (South Africa,
Chair), David Grimes (United States), Edward Pritchett
(United States), Andrea Rapkin (United States), Anne Sza-
rewski (UK), Carolyn Westhoff (United States)) are inter-
national experts in relevant scientific fields (e.g.,
epidemiology, gynecology and cardiology). Specific ques-
tions (legal, ethical, regulatory, etc.) may be addressed by
ad-hoc consultants. The members of the council will
receive remuneration of expenses and an honorarium to
compensate for loss of potential earnings during their
work for SMAC. The members will not be involved in or
paid for the operational conduct of the study.
Study Management
This study will be conducted in accordance with
➢ 'Guidelines for Good Pharmacoepidemiology Practices
(GPP)' issued by the International Society for Pharma-
coepidemiology in 2004
➢ 'Good Epidemiological Practice (GEP) - Proper Con-
duct in Epidemiologic Research' issued by the European
Epidemiology Federation in 2004
➢ The ethical principles that have their origin in the Dec-
laration of Helsinki.
All processes that are relevant for legal compliance of the
study or the integrity of the data are subject to quality con-
trol measures. This includes the development of study
protocols, questionnaires, databases and data entry
screens, the data entry, plausibility checks, validation of
clinical outcomes, reporting of adverse drug reactions,
data analysis, report writing, publications of results,
archiving. The quality control measures are based on the
four-eye principle (i.e., each work process that is relevant
for the overall quality of the study has to be quality con-
trolled by independent second person).
As an additional quality control, the independent Safety
Monitoring and Advisor Board will supervise the study.
Ethics and Privacy
The study starts after all relevant legal, administrative and
ethical requirements have been fulfilled. Information on
the identity of the patients and treating physicians will be
kept separate from the clinical information throughout
the study. Confidentiality of information on study sub-
jects will be maintained. All relevant national data protec-
tion laws will be followed. The study protocol will be
submitted to the relevant Ethics Committees, Institutional
Review Boards and regulatory authorities for comments
and approval.BMC Medical Research Methodology 2009, 9:77 http://www.biomedcentral.com/1471-2288/9/77
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The study subjects will not be placed at risk as a result of
the study. OC prescription takes place independently of
study participation.
Participating physicians will not receive payments for
their time and labor but only for the running costs of their
practice (salaries of staff, maintenance of equipment,
cleaning, rent, etc.). All payments will be completely doc-
umented and will be only based on work actually per-
formed.
Publications
The final study protocol and the results of this study will
be published. In accordance with the International Com-
mittee of Medical Journal Editors (ICMJE) initiative
requiring prior entry of clinical studies in a public registry
as a condition for publication, the study will be registered
in the U.S. National Institutes of Health's protocol regis-
tration database http://ClinicalTrials.gov.
The manuscripts will be approved by the Safety Monitor-
ing and Advisory Board before submission. Bayer Scher-
ing Pharma AG has no right to prevent the publication of
results or to influence the interpretation of data.
Discussion
The feasibility of the study is considered to be very high
because of its similar design to the EURAS-OC study. All
relevant methodological and logistical features of the
study were successfully tested in the EURAS study. E.g., in
the EURAS-OC study a very low loss to follow-up rate of
2.4% was achieved (cf. Follow-up). Therefore, a loss to
follow-up rate in this study of less than 10% is expected.
This is a non-interventional, prospective cohort study
with the limitations inherent to non-experimental
research. I.e., the possibility of bias and residual con-
founding can never be entirely eliminated, and the ability
to infer causation is correspondingly limited [20]. Today,
improved insight into potential sources of bias and con-
founding as well as refinements of statistical and epidemi-
ologic methodology helps to estimate the impact of bias
and residual confounding. However, the difficulty may
remain unresolved when all that exists is a weak associa-
tion. In practical terms, a point in the gradient of declin-
ing relative risk must be reached at which the amount of
bias and residual confounding becomes so small that it
cannot realistically be ruled out [21]. Hazard ratio esti-
mates that are close to unity may not allow differentiation
between causation, bias and confounding.
Different epidemiological methods vary in their suscepti-
bility to different kinds of bias. In the context of this study
- a prospective, controlled, non-interventional cohort
study - the focus here is on the role of detection bias. It is
conceivable that the safety information given to physi-
cians and patients influences the frequency and accuracy
of diagnostic measures for VTE. It is also conceivable that
patients using a newly introduced product are more care-
fully monitored. If so, this may lead to the detection of
otherwise occult VTE cases.
It should be noted here that residual confounding in this
study - as in every other non-interventional study - cannot
be completely excluded. Although all confounders known
for the individual women are documented in detail at
baseline adjustment or stratification cannot be done for
unknown confounders.
However, the chosen design minimizes the impact of
referral and misclassification bias, healthy user effect and
loss to follow-up. Overall, it is expected that the study
design is robust enough to interpret hazard ratios of 1.5 or
higher.
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